Fig. 6: Combined anti-PD-L1 and anti-TIGIT therapies suppress mixed mouse cSCC growth by targeting epithelial and mesenchymal cancer cells.

a Growth kinetics of IgG control and anti-PD-L1-treated mixed cSCCs (n = 8 per group). b–e Percentage of b CD8⁺ T cells (n = 8), c NK cells (n = 8), d GzmB⁺ CD8⁺ T cells (n = 6), and e GzmB⁺ NK cells (n = 6) in IgG control and anti-PD-L1-treated mixed cSCCs. f Growth kinetics of IgG control and anti-CTLA-4-treated mixed cSCCs (n = 8 per group). g–j Percentage of g CD8⁺ T cells (n = 8), h NK cells (n = 8), i GzmB⁺ CD8⁺ T cells (n = 6), and j GzmB⁺ NK cells (n = 6) in IgG control and anti-CTLA-4-treated mixed cSCCs. k Growth kinetics of IgG control, anti-PD-L1, anti-TIGIT, and anti-PD-L1 + anti-TIGIT-treated mixed cSCCs (n = 10 per group). l–o Percentage of l CD8⁺ T cells (n = 10), m NK cells (n = 10), n GzmB⁺ CD8⁺ T cells (n = 7), and o GzmB⁺ NK cells (n = 7) in the indicated mixed cSCCs. p–r Percentage of GFP⁺EpCAM⁺ and GFP⁺EpCAM⁻ cancer cells in the indicated mixed cSCCs (PD-L1 and CTLA-4 experiments: n = 8 per group; PD-L1/TIGIT experiment: n = 10 per group). All data are represented as the mean ± SD, and n values indicate independent tumors. P values are determined by two-way ANOVA test (a, f, k), unpaired two-sided Student’s t-test (b–e, g–j, p, q), and one-way ANOVA with Dunnett’s multiple comparison test (l–o, r). See Supplementary Fig. 2 for the gating strategy (b–e, g–j, l–r). Source data are provided as a Source Data file.